Weekly BIONews and-- "From Point AI to Point B: AI’s next leap in healthcare"

Please join B2DG members and guests for our May 27 morning meeting, which will include the Weekly Updated BIONews followed by a live presentation:
From Point AI to Point B: AI’s next leap in healthcare
Suman Datta
CEO
Velox
AI is moving from pilot to platform in medtech and biotech—transforming how teams drive functions, including market research, payer strategy, medical affairs, and regulatory. In this talk, we’ll unpack what’s driving adoption now, show how a domain-specific AI like Velox can automate high-effort commercial workflows, and explore how healthcare companies and consulting firms are putting it into practice. We’ll close with a candid Q&A on what’s working, what’s hype, and where leaders are placing their bets. This meeting is planned as a highly interactive event. Submitting your questions in advance is welcome and will help shape a fuller discussion on problems that might impact you, your company, your specific corporate function, etc. Please send comments and questions to [Hwachob@bio2devicegroup.org](mailto:Hwachob@bio2devicegroup.org). If you are pressed for time, bring them with you, and we will include them in a formal Q/A.
Date/Time:
May 27, 2025
8:15 am - 10:15 am
8:15- 8:30 AM PDT – networking and info slides
8:30-9:05 – Weekly Updated BIONews and Admin
9:05 – Live Presentation Suman Datta
10:15 Q/A & Networking
Event Location:
Zoom talk: https://us02web.zoom.us/j/89077658197
Event Speaker Bio:
Suman is a commercial and product-focused healthcare leader with 20+ years of experience scaling innovation across PE-backed and global life sciences companies. He has held leadership roles at Amgen, Medtronic, and Siemens Healthineers, and currently serves as CEO of Velox—a health-tech platform now preparing for sale—where he launched an AI-enabled product that automates high-effort commercial workflows and doubled EBITDA in 12 months. Suman has led acquisitions, built and scaled commercial and product teams, and raised over eight figures in capital. His work spans medtech, biotech, and healthcare services, with a focus on leveraging data, technology, and strategic clarity to unlock growth.